key: cord-0336271-313nasz6 authors: LAUNAY, O.; Cachanado, M.; Luong Nguyen, L. B.; Ninove, L.; Lachatre, M.; Ben Ghezala, I.; Bardou, M.; Schmidt -Mutter, C.; Felten, R.; Lacombe, K.; Surgers, L.; Laine, F.; Allain, J.-S.; Botelho-Nevers, E.; Tavolacci, M.-P.; Chidiac, c.; Pavese, P.; Dussol, B.; Priet, S.; Deplanque, D.; Touati, A.; Curci, L.; Konate, E.; Ben Hamouda, N.; Besbes, A.; Nubret, E.; Capelle, F.; Berard, L.; Rousseau, A.; Tartour, E.; Simon, T.; De Lamballerie, X. title: Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine date: 2022-05-27 journal: nan DOI: 10.1101/2022.05.25.22274904 sha: 2e169420f5e0abef3175c67b87300be22f159114 doc_id: 336271 cord_uid: 313nasz6 Background. Variant-adaptated vaccines against coronavirus disease 2019 (COVID-19) as boosters are needed to increase a broader protection against SARS CoV-2 variants. New adjuvanted recombinant protein vaccines as heterologous boosters could maximize the response. Methods. In this randomized, single-blinded, multicenter trial, adults who had received two doses of Pfizer-BioNTech mRNA vaccine (BNT162b2) 3 to7 months before were randomly assigned to receive a boost of BNT162b2, Sanofi/GSK SARS-CoV-2 adjuvanted recombinant protein MV D614 (monovalent parental formulation) or SARS-CoV-2 adjuvanted recombinant protein MV B.1.351 vaccine (monovalent Beta formulation). The primary endpoint was the percentage of subjects with a [≥] 10-fold increase in neutralizing antibody titers for the Wuhan (D614) and B.1.351 (Beta) SARS-CoV-2 viral strains between day 0 and day 15. Findings. The percentages of participants whose neutralizing antibody titers against the Wuhan (D614) SARS-CoV-2 strain increased by a factor [≥]10 between day 0 and day 15 was 55.3% (95% CI 43.4-66.7) in MV D614 group (n=76), 76.1% (64.5-85.4) in MV B.1.351 (Beta) group (n=71) and 63.2% (51.3-73.9) in BNT162b2 group (n=76). These percentages were 44.7% (33.3-56.6), 84.5% (74.0-92.0) and 51.3% (39.6-63.0) for the B.1.351 (Beta) viral strain, respectively. Higher neutralizing antibodies rates against Delta and Omicron BA.1 variants were also elicited after Sanofi/GSK MV Beta vaccine compared to the other vaccines. Comparable reactogenicity profile was observed with the three vaccines. Interpretation. Heterologous boosting with the Sanofi/GSK Beta formulation vaccine resulted in a higher neutralizing antibody response against Beta variant but also the original strain and Delta and Omicron BA.1 variants, compared with mRNA BNT162b2 vaccine or the Sanofi/GSK MVD614 formulation. New vaccines containing Beta spike protein may represent an interesting strategy for broader protection against SARS CoV-2 variants. The efficacy of COVID-19 vaccines for reducing the risk of severe COVID- 19 infection has now been demonstrated in clinical setting, but also in real-world setting. 1 However, questions remain regarding the persistence of immunity and potentially less protection against variant viruses. 2 Therefore, the need for additional doses (boosters) at some interval after the primary vaccination was raised when new waves of COVID-19 cases appeared due to the highly transmissible Delta and Omicron variants. 3 The matching of vaccines from different platforms for priming and boost was recommended after reports of unusual thrombotic events with the adenovirus-based vector vaccine ChAdOx1-nCov-19 vaccine from AstraZeneca/Oxford. 4 Several studies have investigated heterologous prime-boost vaccination combining ChAdOx1-nCov-19 for priming and mRNA vaccine (BNT162b2 or mRNA-1273) for boost. [5] [6] [7] In the observational study of Schmidt et al, the heterologous vaccine regimen induced higher levels of spike-specific IgG, neutralizing antibodies and spike-specific CD4 + T-cells compared to homologous vector vaccine boost and higher or comparable in magnitude to homologous mRNA prime-boost vaccine regimens. 6 Several vaccines developed more recently might offer an interesting alternative for boost in terms of accessibility, cost, reactogenicity, thermostability and acceptability and could be more immunogenic. The vaccines developed by Sanofi are based on recombinant SARS-CoV-2 spike proteins adjuvanted with GSK AS03. 8 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2022. ; https://doi.org/10.1101/2022.05.25.22274904 doi: medRxiv preprint 6/36 protein is of specific interest since it has the potential to provide a different spectrum of crossprotection. The objective of the study was to evaluate the immunogenicity and safety of the adjuvanted recombinant protein vaccine Sanofi/GSK-D614 or -B.1.351 administered as a heterologous booster dose compared to an mRNA vaccine (BNT162b2) administered as a homologous booster dose. We conducted a randomized, single-blinded, multicenter trial across 11 centers in France. Participants were recruited from December 8, 2021, to January 14, 2022. The objective of the study was to evaluate the immunogenicity and safety of a homologous booster dose of a COVID-19 mRNA vaccine (BNT162b2) or adjuvanted recombinant vaccine with adjuvant (Sanofi/GSK MV(D614) formulation or MV B.1.351 (Beta) formulation) in recipients primed with two doses of BNT162b2 between 3 and 7 months earlier. The protocol was conducted in accordance with the Declaration of Helsinki and French law for biomedical research. It was approved by the "CPP Ile de France III" Ethics Committee and the French Health Products Safety Agency (ANSM). This study is registered with the ClinicalTrials.gov identifier NCT05124171 and with the EudraCT identifier 2021-004550-33. Adults aged 18 years and older in good health or with stable health if there was a pre-existing medical history were eligible to participate if they previously received two doses of BNT162b2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) with an interval of 3 to 6 weeks and the second dose administered between 3 and 7 months prior to the administration of the study booster dose. Main exclusion criteria were pregnancy or breastfeeding, acute febrile infection within the previous 72 h and/or presenting symptoms suggestive of COVID-19 within the previous 28 days or having been in contact with an infected individual for the last 14 days before the inclusion visit, virologically documented history of COVID-19 (PCR or serology), use of immunosuppressive medications or any immunosuppressive condition that may reduce the immune response, history of severe postvaccination allergic manifestations or a history of allergic reaction at the time of the first vaccine injection, having received BCG (tuberculosis) vaccine within the previous year or another vaccine within two weeks prior to the boost injection or scheduled to receive a licensed vaccine within 2 weeks after the boost injection. Participants were randomly assigned in a 1:1:1 ratio to receive BNT162b2, MV(D614) vaccine or MV(Beta) vaccine as a third dose. The Sanofi/GSK adjuvanted recombinant protein vaccines are based on pre-fusion S antigens with the transmembrane domain replaced with a trimerization domain with AS03, an oil-in-water emulsion that contains squalene and αtocopherol based immunologic adjuvant manufactured by GSK. 11 Randomization was stratified on center and age group (18-64 years or ≥ 65 years). A web-based randomization system was used (CleanWeb e-CRF, Telemedecine Technologies, S.A.S), with a centralized block randomization list with blocks of size 4 (not communicated to the investigating team). The randomization list was generated by an independent statistician from the trial clinical research unit (URC-EST). Participants were randomized by the investigator. Vaccines were administered intramuscularly into the deltoid muscle on day 0 by trained personnel. The health care professional administering the vaccine was aware of the treatment group because of differences in the preparation of the vaccines. The injection was therefore . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) performed by a person not involved in the study and the investigating physician did not know which vaccine the volunteer had received. The central laboratories performing the antibody analyses were also blinded to limit measurement bias. Blood samples were planned at D0, D3, D15, D28, D90 and D365 for serological analysis. Neutralizing antibodies against the Wuhan (D614) SARS-CoV-2 viral strains and B.1.351 (Beta), Delta and Omicron BA.1 variants were assessed with a microneutralization test as previously described. 12 The test uses clinical strains of SARS-CoV-2 (100 TCID50/well), TMPRSS2-expressing VeroE6 cells and relies on cytopathic effect (CPE) identification at 5 days post-infection. It is a VNT100 (100% of wells lysed in duplicate format). The test is automated in a NSB3 laboratory for all dilution and dispensing steps and for CPE reading. Dilutions tested were 20, 40, 80, 160, 320, 640 and 1280. The range was extended if a titer of 1280 was observed in the first instance. Anti-SARS-CoV-2 IgG antibodies directed against the S1 domain of the virus Spike protein and the nucleocapsid were assessed using the QuantiVac ELISA kit from Euroimmun OE (Lubeck, Germany). Spike specific IFN and IL-2 producing CD4 + T-cells were measured in a subgroup of patients using commercially available kits (IFN Elispot (Diaclone, Besan•on France) and IL-2 Fluorospot (C.T.L Europe, Bonn, Germany). For more detailed description see Supplementary The primary endpoint was the proportion of subjects with an increase rate in neutralizing antibody titers of at least 10-fold, measured by a microneutralization technique, between day 0 and day 15 against D614 SARS-CoV-2 viral strain or B.1.351 variant. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2022. ; https://doi.org/10.1101/2022.05.25.22274904 doi: medRxiv preprint The main other prespecified immunological endpoints were the rate of increase between day 0 and day 15 in neutralizing antibody titers against SARS-CoV-2 Wuhan (D614) and variants Beta, Delta and Omicron BA.1, geometric mean of anti-Spike IgG levels (expressed as BAU/mL) and IFN and IL-2 secreting CD4 + T-cells after stimulation with Spike peptides derived from wild-type SARS-CoV-2 or Omicron variant in each randomized group. Injection-site and systemic solicited adverse events were collected for 7 days and unsolicited adverse events through 28 days after vaccination using diary cards provided to each participant. In the grading of adverse events, the FDA Toxicity Grading Scale (2007) was used (from grade 0, sign/symptom within normal limits to 4, life-threatening adverse event) for the following solicited adverse event: pain, arthralgia, asthenia or malaise, headache, fever, chills, swelling, lymphadenopathy, myalgia, nausea, edema, redness, vomiting; the WHO scale (mild, moderate or severe) was used for the following solicited adverse events, not present in FDA scale: itching, diarrhea, pain in extremities, insomnia. The intent-to-treat (ITT) population included all randomized participants except those with positive nucleoprotein antibody serology at inclusion. Per protocol (PP) population included all randomized vaccinated participants without major protocol deviations, except participants presenting a positive nucleoprotein serology at day 0 or day 15, SARS CoV-2 infection after boost and lost to follow-up participants. The safety population included all randomized participants who received the vaccine booster dose. The immunogenicity analysis was performed on the per-protocol population. As no data was available on the BNT162b2 vaccine, the sample size calculation was based on published data on the mRNA-1273 vaccine in which an increase rate of neutralizing antibody . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2022. ; https://doi.org/10.1101/2022.05.25.22274904 doi: medRxiv preprint 10/36 titer of 23 against ancestral SARS-CoV-2 (D614G) and 32 for the B.1.351 variant after mRNA-1273 boost was described. 13 Using a conservative approach, we considered neutralizing activity to be sufficient if the increase rate was at least 10 at D15. We assumed a proportion of subjects with an increase rate of at least 10 between D0 and D15 of 80%. One hundred subjects per group allowed an estimation of this proportion with a 95% confidence interval (CI) of 7.8%. Thus, a total of 300 volunteers had to be randomized (100 per group). For each viral strain (D614 and B.1.351), the primary endpoint was described using frequencies, percentages and 95% CIs calculated using the exact method. In a post hoc analysis, groups were compared using Chi-2 test. Baseline patient characteristics were described overall and for each group using the number (percentage) for categorical variables and the mean (SD) or median [interquartile range], according to distribution, and range for quantitative variables. For each group, the anti-SARS-CoV-2 IgG antibody titers directed against the S1 domain of the spike protein and the neutralizing antibody titers measured by a microneutralization technique against Wuhan strain (D614) and variants (B.1.351, Delta, Omicron BA.1) measured at day 0, day 15 were described as geometric means with two-sided 95% confidence intervals (95% CI). Adverse reactions and events were described using frequencies and percentages. The statistical analysis was conducted using SAS software version 9.4 (SAS Institute, Inc., Cary, North Carolina, USA). R freeware (version 3.6.3) and GraphPad Prism software (version 9.2.0, San Diego, California USA) were used for the graphs. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) A total of 247 participants who had received two doses of BNT162b2 were randomized from Table 1 ). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 17 Heterologous boosting with Convidecia elicited significantly higher rates of neutralizing antibodies than homologous boosting with CoronaVac. Taken together these results suggest that immunogenicity after heterologous prime-boost leads to comparable or even higher immune response than homologous prime-boost. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2022. ; https://doi.org/10.1101/2022.05.25.22274904 doi: medRxiv preprint These data support our finding of higher immunogenicity induced by a heterologous primingboost with BNT162b2 followed by the Sanofi/GSK adjuvanted recombinant protein vaccine MV(Beta) than the homologous prime-boost with Pfizer BNT162b2. In addition, we showed that the B.1.351 variant (Beta) formulation of the new Sanofi/GSK vaccine provided better cross-neutralization response against both the ancestral strain but also variants such as Delta and Omicron BA.1 compared with the mRNA-based BNT162b2 and also with the Sanofi/GSK MV(D614) vaccine. This same formulation also increased the rate of vaccine-induced double positive producing IFN and IL-2 or IL-2 CD4 + T-cell response (Supplementary Fig 1) . In general, the ability of CD4 + T-cells to produce IL-2 or multiple cytokines is associated with their long-term survival and better pathogen protection. 18, 19 In HIV infection, viral controllers had significantly more CD4 + T-cells co-expressing IL-2 and IFN than other HIV patient categories. 20 This study has some limitations. Compared to the at-risk population for severe forms of SARS-CoV-2 infection, the study population was younger and included a smaller percentage of people ≥65 years than previously planned. Indeed, by the time the study was started, the elderly population had already received a third dose. Another limitation is the priming with a unique vaccine. The primary endpoint was based on an increase in neutralizing antibodies against the Wuhan (D614) and B.1.351 (Beta) strains, which are variants of SARS-CoV-2 that no longer circulate. However neutralizing antibodies against more recent variants were also evidenced. Despite these limitations, our study is the first to report immunization and reactogenicity data on the heterologous boost with an adjuvanted recombinant protein vaccine containing a variant of concern different from the one present at the priming. The higher neutralizing response elicited by the vaccine containing the Beta Spike protein will need further investigations to understand the mechanisms underlying these results. Of interest, this higher immunogenicity was not associated with higher reactogenicity. However, the observed higher immunogenicity . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The increase between the medians at D15 and D0 for the various CD4 + T-cell population is shown. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Efficacy of COVID-19 vaccines: From clinical trials to real life Does infection with or vaccination against SARS CoV-2 lead to lasting immunity? The Lancet Respiratory medicine 2021 Considerations in boosting COVID-19 vaccine immune responses Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, openlabel, randomised, controlled, phase 2 trial Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors Serum Neutralizing Activity Elicited by mRNA-1273 Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Homologous and Heterologous Covid-19 Booster Vaccinations Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial T-cell quality in memory and protection: implications for vaccine design Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents Polyfunctional CD4(+) T cell responses